| Revenue growth | FY26 grew to ₹28,163 Cr vs ₹27,548 Cr in FY25. |
|---|---|
| Margins | EBITDA margin compressed to 21% in FY26 from 25.9% in FY25. |
Growth
FY26 Revenue grew to ₹28,163 Cr; PAT reached ₹3,879 Cr (13.8% margin). Q4FY26 revenue was ₹6,541 Cr.
Outlook
Strong US pipeline with 5 assets filed for FY27; $1Bn+ net cash to fuel growth investments.
Risks
Multiple headwinds mentioned; declining PAT and EBITDA margins year-on-year from FY25 peaks.
Earnings Call filed with BSE, NSE: CIPLA. Summary written with AI assistance from the document.
Cipla Ltd: key numbers
- Share price
- ₹1,327.20
- Market cap
- ₹1,07,221 Cr
- Revenue (annual)
- ₹28,163 Cr
- Net profit (annual)
- ₹3,879 Cr
- P/E (TTM)
- 31.8×Sector 47.4×
- Promoter holding
- 29.21%+0.00% QoQ
- FII holding
- 20.20%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Cipla Ltd
All →Cipla Employee Stock Options
Cipla allotted 12,168 equity shares following the exercise of options under its ESOS and ESAR schemes. This increases the company's total paid-up share capital.
Cipla Management Change
Cipla Ltd announced that Mr. Venkata Sai Mungara has transitioned to a subsidiary role, ceasing to be a Senior Management Personnel effective October 1, 2026.
Cipla Other Announcement
Cipla announced it was assigned an ESG rating of 68 by Niche Ninety Nine Capability and Certifications (OPC) Private Limited, a SEBI-registered rating provider.
Cipla Acquisition
Cipla is notifying shareholders and creditors about a Scheme of Amalgamation with Inzpera Healthsciences, providing them an opportunity to submit representations to the NCLT.
Cipla Partnership
Cipla signed an exclusive licensing and supply agreement with SBP Group’s CTTQ for the drug Rolditamig Deuderuxtecan. This collaboration aims to accelerate therapy access in licensed markets.
Cipla Merger & Restructuring
Cipla Ltd. announced an internal restructuring where Aspergen Limited, India, acquired a 100% stake in Aspergen Inc., USA, from existing group subsidiaries.